GOLFIG-1在化疗耐药转移性结肠癌中的疗效

Chemoimmunotherapy of chemotherapy-refractory metastatic colorectal cancer with gemcitabine plus FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2

目的:评估GOLFIG-1在化疗耐药晚期结直肠癌患者中的疗效和不良反应.方法:选择化疗耐药的晚期结直肠癌患者,先予吉西他滨、奥沙利铂、亚叶酸和氟尿嘧啶化疗,随后予粒细胞巨噬细胞集落刺激因子和IL-2治疗,每14d为1周期.研究的主要终点是生存时间.结果:9例患者入组,早期出组和早期死亡各1例,无完全缓解病例,1例部分缓解,4例稳定,2例进展.中位生存时间为91d(23-325d).2例出现间质性肺炎(考虑为自身免疫的临床症状)患者的生存时间(325d和250d)明显优于其他患者.结论:GOLFIG-1方案在化疗耐药患者中是有效的,特别在那些出现自身免疫的患者中.

AIM：To evaluate the efficacy and safety of gemcitabine plus FOLFOX followed by subcutaneous granulocyte macrophage colonystimulating factor and interleukin-2（GOLFIG-1 regimen）in patients with chemotherapyrefractory metastatic colorectal cancer. METHODS：The patients with chemotherapyrefractory metastatic colorectal cancer were given gemcitabine,oxaliplatin,levofolinic acid, and 5-fluorouracil,followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2.Each cycle lasted for 14 days.The primary endpoint was survival. RESULTS：A total of 9 patients were enrolled,of which 2 could not be evaluated because of early death or refusal of treatment.No complete response was observed.Partial response was observed in 1 patient,stable diseases in 4,and progressive disease in 2.The median survival was 91 days（range：23-325 days）.Two patients with interstitial pneumonitis（considered as clinical signs of autoimmunity）had longer survival（325 and 250 days,respectively）than other patients. CONCLUSION：GOLFIG-1 regimen is effective in patients with chemotherapy-refractory metastatic colorectal cancer,especially in those suffering from autoimmune disorders.